BioMarin price target raised to $73 from $69 at Wedbush

Wedbush analyst Andreas Argyrides raised the firm’s price target on BioMarin to $73 from $69 and keeps a Neutral rating on the shares after the company announced FDA approval of Roctavian to treat adults with severe Hemophilia A without AAVS antibodies. With the U.S. approval in hand, all focus turns to the U.S. commercial strategy given the ongoing failed attempt to launch in the EU since receiving EMA approval in August of last year, the analyst tells investors in a research note.